NanoViricides, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from NanoViricides, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-56.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 74% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
96%Of every $100 the company owns, $96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 78% of Healthcare companies in United States.
Tangible Net Worth Ratio
96%Of every $100 of net worth, $96 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 82% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
NanoViricides, Inc. made a loss over the last year. NanoViricides, Inc. owes $0.10 for every $1 it owns. NanoViricides, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Jun 2025.
P/E ratio
LossNanoViricides, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.88The share price is 3.88 times NanoViricides, Inc.'s book value per share, higher than 64% of Healthcare companies in United States.
Market cap
$35 MThe total market value of all of NanoViricides, Inc.'s shares at today's price (share price × number of shares), smaller than 78% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$9 MWhat NanoViricides, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
$0.36Net worth divided by the number of shares. The share price of $1.39 is 3.9 times this, which is the P/B above.
Return on equity (ROE)
-101.5%NanoViricides, Inc. lost 101.5% of its shareholders' money over the last year, lower than 71% of Healthcare companies in United States.
Owes vs Owns
0.10×NanoViricides, Inc. owes $0.10 for every $1 it owns (low), lower than 86% of Healthcare companies in United States.
Dividend yield
NoneNanoViricides, Inc. does not currently pay a dividend.
Profit growth
LossNanoViricides, Inc. made a loss in each of the last two years.
Interest cover
Not coveredNanoViricides, Inc.'s operating profit did not cover its interest costs in the year to Jun 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For NanoViricides, Inc.: $35 M ÷ $9 M (31 Mar 2026) = 3.9.
What is NanoViricides, Inc.'s return on equity?
NanoViricides, Inc. lost 101.5% of its shareholders' money over the last year, lower than 71% of Healthcare companies in United States.
How much does NanoViricides, Inc. owe compared with what it owns?
NanoViricides, Inc. owes $0.10 for every $1 it owns (low), lower than 86% of Healthcare companies in United States.
Does NanoViricides, Inc. pay a dividend?
No. NanoViricides, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.